Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $1.2 billion.

  • IDEAYA Biosciences' Liabilities and Shareholders Equity fell 441.47% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 1638.85%. This contributed to the annual value of $1.1 billion for FY2024, which is 7311.93% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Liabilities and Shareholders Equity of $1.2 billion as of Q3 2025, which was down 441.47% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2024 and a low of $326.1 million during Q1 2021
  • Its 5-year average for Liabilities and Shareholders Equity is $664.8 million, with a median of $527.6 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 22035.94% in 2021, then tumbled by 441.47% in 2025.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Liabilities and Shareholders Equity stood at $381.3 million in 2021, then rose by 1.74% to $388.0 million in 2022, then skyrocketed by 67.36% to $649.3 million in 2023, then surged by 73.12% to $1.1 billion in 2024, then grew by 5.43% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.